Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma

Trial Profile

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CD19-TAC01 (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Adverse reactions; First in man
  • Acronyms TACTIC-19
  • Sponsors Triumvira
  • Most Recent Events

    • 07 Nov 2019 According to a Triumvira media release, the trial is expected to be initiated by the end of 2019.
    • 08 Oct 2019 According to a Triumvira media release, the trial is expected to be initiated in late 2019.
    • 18 Jun 2019 According to a Triumvira media release, both the U.S. Food & Drug Administration (FDA) and Health Canada have cleared nvestigational New Drug (IND) and Clinical Trial Applications (CTA) for TAC01-CD19 in patients with CD19-postive B-cell malignancies. The trial is expected to be initiated in the third quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top